SYK vs. BSX, BDX, DXCM, RMD, ELV, ISRG, MDT, GILD, AMGN, and VRTX
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Boston Scientific (BSX), Becton, Dickinson and (BDX), DexCom (DXCM), ResMed (RMD), Elevance Health (ELV), Intuitive Surgical (ISRG), Medtronic (MDT), Gilead Sciences (GILD), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
Stryker vs.
Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Stryker has a net margin of 13.86% compared to Boston Scientific's net margin of 6.91%. Stryker's return on equity of 22.17% beat Boston Scientific's return on equity.
77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.2% of Boston Scientific shares are owned by institutional investors. 5.9% of Stryker shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Boston Scientific had 3 more articles in the media than Stryker. MarketBeat recorded 16 mentions for Boston Scientific and 13 mentions for Stryker. Boston Scientific's average media sentiment score of 0.60 beat Stryker's score of 0.60 indicating that Boston Scientific is being referred to more favorably in the news media.
Boston Scientific received 83 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.51% of users gave Boston Scientific an outperform vote while only 64.45% of users gave Stryker an outperform vote.
Stryker presently has a consensus target price of $302.00, indicating a potential upside of 8.46%. Boston Scientific has a consensus target price of $54.00, indicating a potential upside of 4.77%. Given Stryker's higher probable upside, equities research analysts plainly believe Stryker is more favorable than Boston Scientific.
Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Stryker has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Summary
Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools